Ontario-wide Cancer TArgeted Nucleic Acid Evaluation
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Substantial progress has been made in the treatment of cancer through the use of targeted therapies, but what works for one patient might not work for another patient. Certain drugs are now being developed that target specific molecules in the body that are believed to be part of the disease. Biomarkers are specific characteristics of the cancer that may help provide prognostic information (e.g. how well patients will be regardless of the treatments given) or help predict sensitivity or resistance to a specific treatment. The study will collect archival tumor samples (previously collected biopsy or surgical tumor samples) to provide biomarker data about a patient's cancer, which may help their physicians to identify which clinical trials of new drug treatments may be most appropriate for the patient in the future and may also guide the use of approved treatments that may potentially benefit the patient. Another goal of this study is to develop a province-wide registry of targeted gene sequencing testing results that will be made available to cancer researchers. Additional tumour tissue and blood samples collected from all study participants will also be stored in a biobank at the Ontario Institute for Cancer Research for future research. The study will also look at linking data from this study to other health care databases to further collect information about the health care the patients received, including medical tests, clinic visits, or procedures both before and after participating in this study. Having more information about patient health to relate to the DNA sequences may provide new insights into cancer and its treatment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony nowotwór złośliwy w zaawansowanym stadium, który można leczyć systemowo
- •Dostępna próbka tkanki guza do badań genetycznych
- •Wiek co najmniej 18 lat
- •Dobry ogólny stan zdrowia (ECOG 0-1)
- •Spodziewana długość życia powyżej 6 miesięcy
- •Prawidłowe funkcjonowanie organów wewnętrznych
- •Podpisana świadoma zgoda na udział w badaniu
✗ Disqualifies
- •Wcześniejsze leczenie chemią przeciwnowotworową więcej niż 2 razy (z wyjątkiem kandydatów do badań fazy I)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 5, 2026
- Sex
- No restrictions
Locations (7)
Juravinski Cancer Centre
Hamilton, Canada
Kingston General Hospital
Kingston, Canada
London Health Sciences Centre
London, Canada
The Ottawa Hospital Cancer Centre
Ottawa, Canada
Princess Margaret Hospital
Toronto, Canada
Mount Sinai Hospital
Toronto, Canada
Sunnybrook Health Sciences Centre
Toronto, Canada
Trial contact
Samanta Del Rossi
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.